US OptionsDetailed Quotes
CSTM241115C5000
- 0.00
- 0.000.00%
15min DelayClose Nov 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-57.19%PremiumNov 15, 2024Expiry Date6.68Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Constellium Stock Discussion
Sign in to post a comment
News Highlights
$NVIDIA (NVDA.US)$ stock fell 1.30%. Its options trading volume was 2.62 million. Call contracts account for 61.5% of the total trading volume.
$Pfizer (PFE.US)$ stock fell 0.16%. Its options trading volume was 0.30 million. Call contracts account for 57.8% of the total trading volume.The $24 calls expiring August 16 were traded most actively.
Pfizer, $GlaxoSmithKline (GSK.US)$, and $Moderna (MRNA.US)$ are in a ...
$NVIDIA (NVDA.US)$ stock fell 1.30%. Its options trading volume was 2.62 million. Call contracts account for 61.5% of the total trading volume.
$Pfizer (PFE.US)$ stock fell 0.16%. Its options trading volume was 0.30 million. Call contracts account for 57.8% of the total trading volume.The $24 calls expiring August 16 were traded most actively.
Pfizer, $GlaxoSmithKline (GSK.US)$, and $Moderna (MRNA.US)$ are in a ...
+2
28
1
Despite profit boost from unusual items, Constellium's true earnings power may be less. Future profitability is uncertain, and more factors should be considered. Investors should note 2 warning signs in Constellium's investment analysis.
1
Constellium's future performance is deemed crucial for shareholders despite expected slowdown in share price growth. However, investors should be aware of the 3 identified warning signs with the company.
Constellium's decent ROE is overshadowed by its high debt level. A high-quality business is one that can achieve high ROE without debt. Between two companies with the same ROE, the less indebted one is generally preferred.
1
Investors could be wary of potential risks including earnings instability, despite the seemingly stable P/E ratio and stronger-than-expected earnings growth. Unidentified risks might also pressure the P/E ratio, holding back share price despite growth predictions.
Gainers:
In reaction to earnings/guidance:
• $Teva Pharmaceutical Industries (TEVA.US)$ +24%(also announces agreement for opioids settlement), $Enphase Energy (ENPH.US)$ +9.5%, $Spotify Technology (SPOT.US)$ +9.2%, $RPC Inc (RES.US)$ +8.5%, $Chipotle Mexican Grill (CMG.US)$ +8.2%, $Manhattan Associates (MANH.US)$ +8.1%, $Hilton Worldwide (HLT.US)$ +6.7%, $ChampionX (CHX.US)$ +6.1%, $Mr. Cooper Group (COOP.US)$ +5.7%, $Constellium (CSTM.US)$ +5.5%, $Boston Scientific (BSX.US)$ +5.4%, ...
In reaction to earnings/guidance:
• $Teva Pharmaceutical Industries (TEVA.US)$ +24%(also announces agreement for opioids settlement), $Enphase Energy (ENPH.US)$ +9.5%, $Spotify Technology (SPOT.US)$ +9.2%, $RPC Inc (RES.US)$ +8.5%, $Chipotle Mexican Grill (CMG.US)$ +8.2%, $Manhattan Associates (MANH.US)$ +8.1%, $Hilton Worldwide (HLT.US)$ +6.7%, $ChampionX (CHX.US)$ +6.1%, $Mr. Cooper Group (COOP.US)$ +5.7%, $Constellium (CSTM.US)$ +5.5%, $Boston Scientific (BSX.US)$ +5.4%, ...
11
No comment yet
101550592 :